Vertex Pharmaceuticals Inc. (VRTX) News

Vertex Pharmaceuticals Inc. (VRTX): $311.81

-5.79 (-1.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 378

in industry

Filter VRTX News Items

VRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRTX News Highlights

  • VRTX's 30 day story count now stands at 23.
  • Over the past 21 days, the trend for VRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about VRTX are DRUG, ADD and BIIB.

Latest VRTX News From Around the Web

Below are the latest news stories about VERTEX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe

GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.

Yahoo | December 5, 2022

Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?

Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Yahoo | December 5, 2022

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.

Yahoo | December 4, 2022

Those who invested in Vertex Pharmaceuticals (NASDAQ:VRTX) five years ago are up 124%

When you buy a stock there is always a possibility that it could drop 100%. But on a lighter note, a good company can...

Yahoo | December 4, 2022

3 Stocks to Buy Hand Over Fist in December

Here's why they think that AbbVie (NYSE: ABBV), Exelixis (NASDAQ: EXEL), and Vertex Pharmaceuticals (NASDAQ: VRTX) are stocks to buy hand over fist in December. Prosper Junior Bakiny (AbbVie): The end of the year is always a great time to review your investment portfolio. The drugmaker is set to lose U.S. patent protection for its biggest cash cow -- autoimmune-disease medicine Humira -- next year.

Yahoo | December 3, 2022

My 2 Top Growth Stocks to Buy for 2023 and Beyond

Long-time shareholders of these companies can testify that both have patterns of beating the market.

Yahoo | December 3, 2022

12 Top Stocks to Buy in December

The number 12 is tightly linked with December. It's the 12th month, of course. There are 12 days of Christmas, according to the traditional carol. Allow me to add one more connection with 12 to the list.

Yahoo | December 3, 2022

Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.

Yahoo | December 2, 2022

If You Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, This Is How Much You Would Have Today

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a bright spot in this year's bear market. The past few years have brought Vertex ups and downs. Vertex stock was trading at about $140 exactly five years ago.

Yahoo | December 2, 2022

3 Healthcare Stocks to Buy and Hold for the Next 10 Years

If you're looking to add more stocks to your portfolio right now, here are three top healthcare stocks to consider when formulating your list of long-term buys. Vertex Pharmaceuticals (NASDAQ: VRTX) has a near monopoly over the multibillion-dollar cystic fibrosis treatment industry with its portfolio of medicines. In a patient with cystic fibrosis, the CFTR gene becomes mutated, which means this protein is not able to function normally.

Yahoo | December 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5928 seconds.